Three se­nior Chimerix ex­ecs to hold the fort to re­place de­part­ing CEO Berrey

Michelle Berrey — the woman who re­placed Chimerix CEO Ken­neth Moch in 2014 af­ter the com­pa­ny no­to­ri­ous­ly de­nied a dy­ing child com­pas­sion­ate use of its ex­per­i­men­tal treat­ment — has stepped down for undis­closed rea­sons, the Durham, North Car­oli­na-based drug de­vel­op­er said on Wednes­day.

Berrey, who served as the com­pa­ny’s chief med­ical of­fi­cer pri­or to be­com­ing CEO, came to Chimerix from Phar­mas­set where she was al­so CMO un­til the com­pa­ny was swal­lowed by Gilead in 2012, en­abling the lat­ter to gen­er­ate bil­lions in hep C drug sales. She steered the ship at Chimerix as the com­pa­ny sought to spin set­back af­ter set­back in the late-stage de­vel­op­men­tal pro­gram of its oral an­tivi­ral drug, brin­cid­o­fovir, for the pre­ven­tion of cy­tomegalovirus (CMV) dis­ease in kid­ney trans­plant pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER